CSB 2.012 Note961.14 (2) (nd) 16m. Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register December 2017 No. 744, eff. 12-4-17; correction made under s. 35.17, Stats., Register December 2017 No. 744; CR 18-023: cr. Register June 2019 No. 762, eff. 7-1-19. CSB 2.012 NoteCSB 2.60 Addition of FUB-AMB to schedule I. Section 961.14 (4) (tb) 43., Stats., is created to read: CSB 2.012 Note961.14 (4) (tb) 43. methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, commonly known as FUB-AMB, MMB-FUBINACA or AMB-FUBINACA.
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register December 2017 No. 744, eff. 12-11-17; correction made under s. 35.17, Stats., Register December 2017 No. 744; CR 18-022: cr. Register June 2019 No. 762, eff. 7-1-19. CSB 2.012 NoteCSB 2.61 Addition of MT-45 to schedule I. Section 961.14 (2) (rk), Stats., is created to read: CSB 2.012 Note961.14 (2) (rk) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register January 2018 No. 745, eff. 1-22-18; correction made under s. 35.17, Stats., Register January 2018 No. 745; CR 18-069: cr. Register June 2019 No. 762, eff. 7-1-19. CSB 2.012 NoteCSB 2.62 Addition of para-chloroisobutyryl fentanyl to schedule I. Section 961.14 (2) (nd) 16s., Stats., is created to read: CSB 2.012 Note961.14 (2) (nd) 16s. Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2018 No. 747, eff. 3-12-18; CR 18-070: cr. Register June 2019 No. 762, eff. 7-1-19. CSB 2.012 NoteCSB 2.63 Addition of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA to schedule I. Section 961.14 (4) (tb) 44., 45., 46., 47., and 48., Stats., are created to read: CSB 2.012 Note961.14 (4) (tb) 44. Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, commonly known as NM2201.
CSB 2.012 Note45. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide, commonly known as 5F-AB-PINACA.
CSB 2.012 Note46. 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, commonly known as 4-CN-CUMYL-BUTINACA.
CSB 2.012 Note47. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate, commonly known as MMB-CHMICA.
CSB 2.012 Note48. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide, commonly known as 5F-CUMYL-P7AICA.
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2018 No. 747, eff. 3-12-18; cr. Affirmative action order under s. 961.11 (4), Stats., Register August 2018 No. 752, eff. 8-13-18; correction made under s. 35.17, Stats., Register August 2018 No. 752; CR 19-010: cr. Register June 2020 No. 774, eff. 7-1-20; correction made under s. 35.17, Stats., Register June 2021 No. 786. CSB 2.012 NoteCSB 2.64 Addition of N-Ethylpentylone to schedule I. Section 961.14 (7) (L) 34., Stats., is created to read: CSB 2.012 Note961.14 (7) (L) 34. N-Ethylpentylone, commonly known as ephylone.
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2018 No. 754, eff. 10-8-18; CR 19-011: cr. Register June 2020 No. 774, eff. 7-1-20. CSB 2.012 NoteCSB 2.65 Addition of approved cannabidiol drugs to schedule V. Section 961.22 (7), Stats., is created to read: CSB 2.012 Note961.22 (7) Approved cannabidiol drugs. A drug product in finished dosage formulation that has been approved by the United States food and drug administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4g), Stats., Register October 2018 No. 754, eff. 10-15-18; CR 19-012: cr. Register June 2020 No. 774, eff. 7-1-20. CSB 2.012 NoteCSB 2.66 Addition of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 to schedule I. Section 961.14 (4) (tb), 49., 50., 51., 52., and 53., Stats., are created to read: CSB 2.012 Note961.14 (4) (tb) 49. Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-EDMB-PINACA.
CSB 2.012 Note50. Methyl 2-(1-(5-fluoropentyl)-1-indole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-MDMB-PICA.
CSB 2.012 Note51. N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, commonly known as FUB-AKB48, FUB-APINACA or AKB48 N-(4-FLUOROBENZYL).
CSB 2.012 Note52. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, commonly known as 5F-CUMYL-PINACA or SGT-25.
CSB 2.012 Note53. (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone, commonly known as FUB-144.
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2019 No. 759, eff. 3-11-19; CR 20-048: cr. Register June 2021 No. 786, eff. 7-1-21. CSB 2.012 NoteCSB 2.67 Addition of Brexanolone and Solriamfetol to schedule IV. Section 961.20 (2) (ap) and (2m) (g), Stats., are created to read: CSB 2.012 Note961.20 (2) (ap) Brexanolone;
CSB 2.012 Note(2m) (g) Solriamfetol.
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2019 No. 763, eff. 7-22-19; CR 20-049: cr. Register June 2021 No. 786, eff. 7-1-21; correction in (2) (ap) made under s. 35.17, Stats., Register June 2021 No. 785. CSB 2.012 NoteCSB 2.68 Addition of N-Ethylhexedrone, a-PHP, 4-MEAP, MPHP, PV8 and 4-chloro-a-PVP to schedule I. Section 961.14 (7) (L) 35. to 40., Stats., is created to read: CSB 2.012 Note961.14 (7) (L) 35. N-Ethylhexedrone.
CSB 2.012 Note36. Alpha-pyrrolidinohexanophenone, commonly known as a-PHP.
CSB 2.012 Note37. 4-methyl-alpha-ethylainopentiophenone, commonly known as 4-MEAP.
CSB 2.012 Note38. 4’-methyl-alpha-pyrrolidinohexiophenone, commonly known as MPHP.
CSB 2.012 Note39. Alpha-pyrrolidinoheptaphenone, commonly known as PV8.
CSB 2.012 Note40. 4’-chloro-alpha-pyrrolidinovalerophenone, commonly known as 4-chloro-a-PVP.
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4g), Stats., Register August 2019 No. 764, eff. 8-19-19; CR 20-050: cr. Register June 2021 No. 786, eff. 7-1-21. CSB 2.012 NoteCSB 2.69 Addition of Noroxymorphone to schedule II. Section 961.16 (2) (a) 10m., Stats., is created to read: CSB 2.012 Note961.16 (2) (a) 10m. Noroxymorphone.
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2019 No. 767, eff. 11-11-19; CR 20-051: cr. Register June 2021 No. 786, eff. 7-1-21. CSB 2.012 NoteCSB 2.70 Scheduling 4F-MDMB-BINACA and MMB-FUBICA. Section 961.14 (4) (tb) 38m. and 43m., Stats., are created to read: CSB 2.012 Note961.14 (4) (tb) 38m. Methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 4F-MDMB-BINACA or 4F-MDMB-BUTINACA.
CSB 2.012 Note43m. Methyl 2-(1-(4-fluorobenzyl)-1H-indole-3-carboxamido)-3-methylbutanoate, commonly known as MMB-FUBICA or AMB-FUBICA.
CSB 2.012 HistoryHistory: EmR2017: emerg. cr., eff. 6-26-20; CR 20-022: cr. Register May 2021 No. 785, eff. 6-1-21. CSB 2.012 NoteCSB 2.71 Addition of lasmiditan to schedule V. Section 961.22 (8), Stats., is created to read: CSB 2.012 Note961.22 (8). Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide].
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2020 No.771, eff. 3-23-20; CR 20-058: cr. Register July 2021 No. 787, eff. 8-1-21. CSB 2.012 NoteCSB 2.72 Scheduling of isotonitazene and 1P-LSD. Section 961.14 (2) (pe) and (4) (jm), Stats., are created to read: CSB 2.012 Note961.14 (2) (pe) Isotonitazene;
CSB 2.012 Note961.14 (4) (jm) 1-propionyl-lysergic acid diethylamide, commonly known as 1P-LSD;
CSB 2.012 HistoryHistory: EmR2013: emerg. cr., eff. 6-5-20; CR 20-023: cr. Register May 2021 No. 785, eff. 6-1-21; correction made under s. 35.17, Stats., Register May 2021 No. 785. CSB 2.012 NoteCSB 2.73 Addition of cenobamate to schedule V. Section 961.22 (9), Stats., is created to read: CSB 2.012 Note961.22 (9) CENOBAMATE Cenobamate ([(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate; 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester)
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register May 2020 No. 773, eff. 5-18-20; CR 20-075: cr. Register July 2021 No. 787, eff. 8-1-21. CSB 2.012 NoteCSB 2.74 Addition of Lemborexant to schedule IV. Section 961.20 (2) (eqm), Stats., is created to read: CSB 2.012 Note961.20 (2) (eqm) Lemborexant.
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2020 No.771, eff. 5-18-20; CR 20-076: cr. Register July 2021 No. 787, eff. 8-1-21; correction made under s. 35.17, Stats., Register July 2021 No. 787. CSB 2.012 NoteCSB 2.75 Exclusion of approved cannabidiol drugs from schedule I. (1) Section 961.14 (4) (t) 4., Stats., is created to read: CSB 2.012 Note961.14 (4) (t) 4. A drug product in finished dosage formulation that has been approved by the United States food and drug administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.
CSB 2.012 Note(2) Section 961.22 (7) is repealed.
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4g), Stats., Register June 2020 No. 774, eff. 6-29-20; CR 20-077: cr. Register July 2021 No. 787, eff. 8-1-21. CSB 2.012 NoteCSB 2.76 Addition of norfentanyl to schedule II. (1) Section 961.16 (8) (b), Stats., is renumbered 961.16 (8) (b) (intro.) and amended to read:
CSB 2.012 Note961.16 (8) (b) An immediate precursor to fentanyl, including all of the following:
CSB 2.012 Note1. 4-anilino-N-phenethyl-4-piperidine, commonly known as ANPP.
CSB 2.012 Note2. N-phenyl-N-(piperidin-4-yl)propionamide, commonly known as norfentanyl.
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register June 2020 No. 774, eff. 6-29-20; CR 20-078: cr. Register July 2021 No. 787, eff. 8-1-21. CSB 2.012 NoteCSB 2.77 Scheduling of flualprazolam. Section 961.20 (2) (ef), Stats., is created to read: CSB 2.012 Note961.20 (2) (ef) Flualprazolam;
CSB 2.012 HistoryHistory: EmR1037: emerg. cr., eff. 10-27-20; CR 20-078: cr. Register July 2021 No. 787, eff. 8-1-21; correction made under s. 35.17, Stats., Register July 2021 No. 787. CSB 2.012 NoteCSB 2.78 Addition of crotonyl fentanyl to schedule I. Section 961.14 (2) (nd) 9m., Stats., is created to read: CSB 2.012 Note961.14 (2) (nd) 9m. Crotonyl Fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2- enamide);
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2020 No. 779, eff. 11-23-20; CR 22-011: cr. Register June 2023 No. 810, eff. 7-1-23; correction made under s. 35.17, Stats., Register June 2023 No. 810. CSB 2.012 NoteCSB 2.79 Addition of remimazolam to schedule IV. Section 961.20 (2) (mo), Stats., is created to read: CSB 2.012 Note961.20 (2) (mo) Remimazolam;
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2020 No. 779, eff. 11-23-20; CR 22-014: cr. Register June 2023 No. 810, eff. 7-1-23; correction made under s. 35.17, Stats., Register June 2023 No. 810. CSB 2.012 NoteCSB 2.80 Scheduling of oliceridine. Section 961.16 (3) (ta), Stats., is created to read: CSB 2.012 Note961.16 (3) (ta) Oliceridine;
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register December 2020 No. 780, eff. 12-14-20; CR 21-098: cr. Register August 2022 No. 800, eff. 9-1-22. CSB 2.012 NoteCSB 2.81 Addition of brorphine to schedule I. Section 961.14 (2) (et), Stats., is created to read: CSB 2.012 Note961.14 (2) (et) Brorphine;
CSB 2.012 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register May 2021 No. 785, eff. 4-26-21; correction made under s. 35.17, Stats., Register May 2021 No. 785; CR 22-016: cr. Register June 2023 No. 810, eff. 7-1-23; correction made under s. 35.17, Stats., Register June 2023 No. 810. CSB 2.012 NoteCSB 2.82 Addition of Serdexmethylphenidate to schedule IV. Section 961.20 (2m) (em), Stats., is created to read:
